MX2022016236A - Metodos de tratamiento del trastorno del espectro de la neuromielitis optica. - Google Patents
Metodos de tratamiento del trastorno del espectro de la neuromielitis optica.Info
- Publication number
- MX2022016236A MX2022016236A MX2022016236A MX2022016236A MX2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- spectrum disorder
- neuromyelitis optica
- optica spectrum
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046133P | 2020-06-30 | 2020-06-30 | |
| US202063052093P | 2020-07-15 | 2020-07-15 | |
| US202063071092P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/039911 WO2022006283A2 (en) | 2020-06-30 | 2021-06-30 | Methods of treating neuromyelitis optica spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016236A true MX2022016236A (es) | 2023-03-29 |
Family
ID=79321915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016236A MX2022016236A (es) | 2020-06-30 | 2021-06-30 | Metodos de tratamiento del trastorno del espectro de la neuromielitis optica. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230406928A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4172211A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023534916A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230030642A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116234571A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021299307A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026747A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3178954A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299381A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016236A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022006283A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7900888B2 (ja) * | 2020-10-29 | 2026-08-05 | ビエラ バイオ インコーポレイテッド | 自己免疫疾患を治療するための抗cd19抗体の使用 |
| CN117797245A (zh) * | 2023-12-29 | 2024-04-02 | 广州赛莱拉干细胞科技股份有限公司 | 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101977843B1 (ko) * | 2017-02-16 | 2019-05-13 | 국립암센터 | 시신경척수염 및 다발성경화증의 선별을 위한 바이오마커 및 이의 이용 |
| CN110522908A (zh) * | 2018-05-25 | 2019-12-03 | 荣昌生物制药(烟台)有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
| EP3959241A4 (en) * | 2019-04-24 | 2023-01-25 | Viela Bio, Inc. | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE |
| JP7900888B2 (ja) * | 2020-10-29 | 2026-08-05 | ビエラ バイオ インコーポレイテッド | 自己免疫疾患を治療するための抗cd19抗体の使用 |
-
2021
- 2021-06-30 JP JP2022581408A patent/JP2023534916A/ja active Pending
- 2021-06-30 KR KR1020237002980A patent/KR20230030642A/ko active Pending
- 2021-06-30 MX MX2022016236A patent/MX2022016236A/es unknown
- 2021-06-30 CA CA3178954A patent/CA3178954A1/en active Pending
- 2021-06-30 EP EP21834411.7A patent/EP4172211A4/en active Pending
- 2021-06-30 WO PCT/US2021/039911 patent/WO2022006283A2/en not_active Ceased
- 2021-06-30 IL IL299381A patent/IL299381A/en unknown
- 2021-06-30 BR BR112022026747A patent/BR112022026747A2/pt unknown
- 2021-06-30 CN CN202180046409.5A patent/CN116234571A/zh active Pending
- 2021-06-30 AU AU2021299307A patent/AU2021299307A1/en active Pending
-
2022
- 2022-12-28 US US18/147,287 patent/US20230406928A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022026747A2 (pt) | 2023-01-24 |
| WO2022006283A2 (en) | 2022-01-06 |
| CA3178954A1 (en) | 2022-01-06 |
| KR20230030642A (ko) | 2023-03-06 |
| EP4172211A4 (en) | 2024-07-10 |
| EP4172211A2 (en) | 2023-05-03 |
| US20230406928A1 (en) | 2023-12-21 |
| WO2022006283A3 (en) | 2022-02-03 |
| AU2021299307A1 (en) | 2022-12-22 |
| IL299381A (en) | 2023-02-01 |
| CN116234571A (zh) | 2023-06-06 |
| JP2023534916A (ja) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3878862A3 (en) | Anti-coronavirus antibodies and methods of use | |
| WO2022006283A3 (en) | Methods of treating neuromyelitis optica spectrum disorder | |
| MX2022016061A (es) | Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos. | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| BRPI0515884A (pt) | métodos de diagnóstico e tratamento de complicações da gravidez | |
| EA202190841A1 (ru) | Композиции для снижения уровней мочевой кислоты в сыворотке крови | |
| WO2020209988A3 (en) | Diverse marker panel for ptsd diagnosis and treatment | |
| WO2020185541A3 (en) | Zilucoplan as deep tissue penetrating c5 inhibitor | |
| BR112021024634A2 (pt) | Método de tratamento ou prevenção de um distúrbio, doença ou condição aliviada pela estimulação ou modulação da expressão de colágeno | |
| MX2022011050A (es) | Anticuerpos anti-cd36 y su uso para tratar cancer. | |
| MX2022015772A (es) | Proteínas enpp1 o enpp3 solubles y sus usos. | |
| EA202193111A1 (ru) | Композиции и способы для лечения рака | |
| WO2021257816A3 (en) | Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury | |
| WO2019241730A8 (en) | Increasing immune activity through modulation of postcellular signaling factors | |
| MX2025008918A (es) | Tratamiento para la rinosinusitis cronica con anticuerpos anti-tslp | |
| WO2021195470A3 (en) | Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2 | |
| EA202092487A1 (ru) | Ферменты кинурениназы человека и их применение | |
| MA47550B2 (fr) | Systèmes et procédés de préparation de boissons contenant de l'éthanol | |
| MX2025004473A (es) | Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos | |
| EA202090427A1 (ru) | Композиции и способы лечения атопического дерматита и выбора лечения | |
| ZA202107917B (en) | Methods of treating borderline personality disorder | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
| MX2024008767A (es) | Agente de union de acido polisialico de-n-acetilado (dpsa) y metodo de uso del mismo. | |
| MX2025008198A (es) | Terapia con moléculas de proteínas de unión a lípidos |